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ABSTRACT: Acute hepatitis results from oxidative
stress triggered by hepatotoxic drugs causing liver
injury and the activation of caspases cascade. The
glutathione antioxidant system protects against re-
active oxygen species and mitigates development
of these processes. The effectiveness of silymarin,
a polyphenolic flavonoid, essenthiale, composed of
phosphatidyl choline, and melaxen, a melatonin-
correcting drug, as hepatoprotectors has been investi-
gated. The variation of 6-sulfatoxymelatonin (aMT6s),
resulting from the biotransformation of melatonin, and
GSH has been measured. The activities of caspase-
1 and caspase-3, glutathione antioxidant system, and
NADPH-generating enzymes were determined. The
aMT6s decreases in patients with drug hepatitis and re-
covers with administration of mexalen. GSH increased
in the presence of the studied hepatoprotectors. Patho-
logically activated caspase-1 and caspase-3 decreased
their activities in the presence of hepatoprotectors with
melaxen showing the highest effect. The positive effect
of melatonin appears to be related to the suppression of
decompensation of the glutathione antioxidant system
functions, recovery of liver redox status, and the atten-
uation of inhibition of the NADPH supply. C© 2015 Wi-
ley Periodicals, Inc. J. Biochem. Mol. Toxicol. 29:449–457,
2015; View this article online at wileyonlinelibrary.com.
DOI 10.1002/jbt.21705
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INTRODUCTION
Acute hepatitis often occurs as a result of the for-
mation of reactive metabolites in the liver. Hepatotoxic
drugs can injure the hepatocyte directly via production
of free radical or through metabolite peroxidation of
membrane lipids. Reactive oxygen species (ROS) have
been implicated in the drug-induced injury. In tubercu-
losis, inflammatory mediators and oxidative stress may
potentiate drugs hepatotoxicity. In these processes, the
death ligands, Fas ligand, tumor necrosis factor α
(TNF-α), and their cognate receptors can induce liver
injury by triggering hepatocyte apoptosis and necrosis
[1], activating in the caspases cascade. Caspase-1 and
caspase-3 are inflammatory and apoptotic enzymes,
signaling ongoing cell damaging processes during hep-
atitis [2]. Apoptosis may be controlled by the redox
status of the hepatocyte [3, 4], constituting a defense
mechanism against acute hepatitis [5, 6].
The tissue redox status depends on complex en-
zymatic mechanisms, whereas the glutathione antiox-
idant system plays a central role. Glutathione in the
reduced (GSH) or oxidized (GSSG) forms, glutathione
peroxidase (GPx; EC 1.11.1.9), glutathione reductase
(GRx; EC 1.6.4.2), and glutathione S-transferase (GST;
EC 2.5.1.18) are involved in the glutathione antiox-
idant system [7–10]. The system requires supply of
NADPH provided by glucose-6-phosphate dehydro-
genase (G6PD; EC 1.1.1.49) or NADP–isocitrate dehy-
drogenase (NADP–IDH; EC 1.1.1.42) [11, 12].
GSH in its reduced form is thought to be the
most important intracellular defense against ROS. Its
free sulfhydryl group provides an antenna for attack
by different oxidative species [7]. GPx uses GSH as
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substrate to neutralize hydrogen peroxide and lipid
peroxides. Oxidized glutathione (GSSG) is further re-
cycled to its reduced form by GRx using NADPH [8, 9].
One of the major cellular suppliers of NADPH for the
glutathione antioxidant system is the pentose phos-
phate pathway, where G6PD catalyzes transformation
of glucose-6-phosphate into 6-phosphogluconolactone
with production of NADPH [11]. The needs of the
GPx/GRx system for NADPH enhances the disorders
disruption of the tissue antioxidative defenses [13]. Al-
ternatively NADPH can be generated by NADP–IDH,
which promotes oxidizing decarboxylation of isoci-
trate into 2-oxoglutarate [12]. Additionally, GST is in-
volved in the antioxidant protection and detoxification
of harmful toxic compounds using GSH as a substrate
[10], avoiding activation of the reactive oxidative cas-
cade. Therefore, the tissue glutathione antioxidant sys-
tem has clinical importance.
The glutathione antioxidant system can fail in the
defense of liver from injury caused by antituberculosis
drugs. In such instance, hepatoprotectors can assist
in recovery of the antioxidative status and regenerate
damaged tissue. Silymarin, a herbal drug, exhibits
hepatoprotective properties due to antioxidant power
of the polyphenolic flavonoids [14]. Essenthiale com-
posed of phosphatidyl choline promotes regeneration
of cell membranes and suppresses oxidative stress
[15]. Melatonin secreted by several body tissues is
involved in synchronization of the organism circadian
and seasonal biorhythms and present at high concen-
trations in the mitochondria and cell nucleus, whereas
can act as a free radical scavenger [16] effectively
protecting membranes, nucleus, and mitochondrial
DNA. The possible protective role of melatonin against
pathological processes during drug-induced hepatitis
is still unknown. Melaxen, a melatonin-regulating
drug, could be used to understand its role in liver
protection [17]. 6-Sulfatoxymelatonin (aMT6s), major
metabolite of melatonin [18], was used to study the
hormone metabolism under stress conditions [19].
This work aims to evaluate effectiveness of hep-
atoprotectors as potential activators of glutathione an-
tioxidant system in the mitigation of inflammatory
and apoptotic processes and protection of liver tissue
against injuries caused by antituberculosis drugs.
MATERIAL AND METHODS
Study Subject and Sample Groups
A group of 131 individuals, adult man and women
were included in the present study (Table 1). Sixty-
six individuals with drug-induced hepatitis including
42 man (64%) and 24 woman (36%), age ranging from
18 to 56 years, were used as the experimental groups.
All patients who suffered from lungs tuberculosis were
treated at the Voronezh regional antitubercular clinics.
Diagnoses of a drug-induced hepatitis were made us-
ing evaluation of the clinical symptoms, biochemical
blood analysis, and an ultrasound exam of the liver.
On average, the disease lasted 2.6 ± 0.4 month. The
control group was composed of 65 generally healthy
people, age ranging from 21 to 52 years, with normal
parameters of the general and biochemical blood sam-
ples.
Drug-induced hepatitis patients were subdivided
into two groups. The first group included 35 patients
submitted for 10 days to a standard treatment with
hepatoprotectors (silymarine and essenthiale). The sec-
ond group of 31 individuals received the same stan-
dard therapy supplemented with one tablet per day
of melaxen (Unifarm, New York, NY, USA) contain-
ing 3 mg melatonin. The treatment was administered
30–40 min before bed time for 10 days.
Blood and Urine Samples
Blood serum and urine samples were collected
from all individuals twice, at the beginning and end
of the study, using standard sampling methods.
Biochemical Parameters Analysis
The BÜHLMANN 6-sulfatoxymelatonin ELISA kit
(EK-M6S) was used for the direct and quantitative de-
termination of aMT6s in human urine. The assay used
a capture antibody principal based on polyclonal an-
tibody specific for rabbit immunoglobulin coated onto
the microtiter plates. The analysis requires 5 μL of urine
and has a range sensitivity of 0.8–40 ng/mL. GSH con-
centration was determined through the reaction with
5,5-dithio-bis-(2-nitrobenzoic) acid [20]. Protein con-
tent in blood serum samples was determined according
to Lowry [21], using a bovine serum albumin calibra-
tion curve.
Measurement of Enzyme Activity
Сaspase-1 and caspase-3 activities in blood serum
were determined using colorimetric assay kits for
caspase-1 and caspase-3 (Sigma-Aldrich Lda, Dorset,
UK), respectively. The caspase activity was mea-
sured at the 405 nm (molar extinction coefficient =
10.5) as the yield of p-nitroaniline resulting from the
hydrolysis of the peptide substrates acetyl-tyr-Val-
Ala-Asp-p-nitroanilide (Ac-YVAD-pnA) (for caspase-1)
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TABLE 1. Clinical Study Sample Major Features
Control Group I Group II
N 65 66
Man 42 (64%) 42 (64%)
Woman 24 (36%) 24 (36%)
Ages range (years) 21–52 18–56
Mean disease duration (months) – 2.6 ± 0.4
Groups’ size 65 35 31
Diagnoses Yes Yes Yes
Therapy treatment None Silymarine, essentiale +Melaxen
All individuals included in this study have been diagnosed for drug-induced hepatitis or its absence, based on clinical symptoms, biochemical blood analysis, and
ultrasound examination. na – not applicable
and acetyl-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DeVD-
pnA) (for caspase-3). Caspases specific activity was
expressed in picomoles of the product formed during
1 min per 1 mg of the protein.
Activities of other enzymes in blood serum were
measured spectrophotometrically at the 340 nm with
a Hitachi U-1900 spectrophotometer (Richmond Scien-
tific, Lancashire, UK). Enzyme activity was expressed
in catalytic units per 1 mL of serum and the enzyme spe-
cific activity as the number of catalytic units per 1 mg of
protein. One unit of catalytic activity (U) was defined as
the amount of the enzyme activity performing the con-
version of 1 μmol of substrate per minute at 25°С. GRx
activity was measured in a reagent mixture with 50 mM
potassium phosphate buffer (pH 7.4), 1 mМ ethylene-
diaminetetraacetic acid (EDTA), 0.16 mM NADPH, and
0.8 mM oxidized glutathione (GSSG). GPx activity was
assayed in the reagent mixture with 50 mM potas-
sium phosphate buffer (pH 7.4), 1 mM EDTA, 0.12 mM
NАDPМ, 0.85 mM GSH, 0.37 mM H2О2, and 1 U/mL
GR. GST activity was determined using 1-chloro 2,4-
dinitro benzene (CDNB) [22] in a reagent mixture con-
taining 0.1 M potassium phosphate buffer (pH 6.5),
10 mM GSH, and 1 mM CDNB. G6PD activity was
measured in the reagent mixture with 0.05 mM Tris-
HCl buffer (pH 7.8), 3.2 mM glucose-6-phosphate, and
0.25 mM NADP. NADP–IDH activity was assayed in
0.05 mm Tris-HCl buffer (pH 7.8) with 1.5 mM isoci-
trate and 0.25 mM NADP.
All enzymatic reactions have started by the ad-
dition of 100 μL of blood serum to the reagent
mixtures.
Statistical Analysis
Standard statistical methods were applied to eval-
uate the obtained data including calculation of mean
values, SEM, Student’s t-criterion, and the nonparamet-
ric Wilcoxon test using STATISTICA 6.0 software (Stat-
Soft, Tulsa, OK, USA). Differences between the sample
parameters and enzyme activities were considered sta-
tistically significant at p  0.05.
Ethical Issues
This study was approved by the Ethical Commit-
tee of the Voronezh State Medical Academy governed
by the Ministry of Health of Russian Federation. All
procedures were carried out in accordance with The
Code of Ethics of the World Medical Association (Dec-
laration of Helsinki of 1975) for experiments involving
humans.
Reagents
Chemicals used in this study were of the highest
analytical grade available. NADP, NADPH, and GSH
were obtained from Sigma. D,L-Isocitrate (trisodium
salt) and glucose-6-phosphate were from Sigma Chem-
ical (London, UK), and Tris was supplied by Serva
(Germany).
RESULTS
The major features of the subjects included in the
present study are shown in Table 1. The drug-induced
hepatitis was diagnosed based on a battery of three clin-
ical tests, e.g., clinical observations, biochemical blood
analysis, and ultrasound examinations. The candidates
suffering from other diseases that could significantly
increase the oxidative stress and affect glutathione
antioxidant system activity such as viral hepatitis, ma-
lignant tumors, acute myocardial infarction, or acute
impairment of the cerebral blood stream were excluded
from this study.
The activity of caspases in blood serum of all
patients with drug-induced hepatitis significantly ex-
ceeded the normal values. The specific activity of
J Biochem Molecular Toxicology DOI 10.1002/jbt
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FIGURE 1. Variation of caspase-1 (A) and caspase-3 (B) specific catalytic activity in blood serum of control group (1), in patients with drug-
induced hepatitis, at the beginning (first column) and after 10 days (second column) of traditional therapy administration (2), and traditional
therapy combined with melaxen (3): before (first column) and after (second column) therapy.
caspase-1 and caspase-3 in blood serum was 2.5-fold
(p < 0.05) and 1.7-fold (p < 0.05) higher, respectively,
when compared to the corresponding activities of the
control group. The standard therapy decreased the
activity of caspase-1 and caspase-3 by 1.6- and 1.1-
fold, respectively (p < 0.05). Additionally, melaxen
administration inhibited caspases activity in a more
profound way, which was, respectively, 2.2- and 1.6-
fold lower when compared to the values before the on-
set of therapy p < 0.05 (Figure 1). These results indicate
that inflammatory and apoptotic processes undergoing
during the drug-induced hepatitis are accompanied by
an increase in the caspases’ activity that seem to be ef-
fectively inhibited by the hepatoprotectors particularly
in the presence of melaxen.
Quantification of the aMT6s level in urine revealed
a difference between the control group (8.99 ng·mL−1)
and the patients (6.21 ng·mL−1) before the treatment
(Figure 2). The standard and aided melaxen therapies
allowed the recovery of aMT6s levels at 11.7% and
to control (9.12 ng·mL−1) levels, respectively. The re-
sults between control and experimental groups before
the therapy and between the ontset and the final ther-
apy with melaxen are statistically different, suggesting
that melaxen enhances melatonin levels in the patient’s
blood and thus protects the liver.
Changes in the content of GSH blood serum in
the control and experimental groups before and af-
ter 10 days of therapy indicate that consumption of
reduced glutathione increases in patients with drug-
induced hepatitis (Figure 2). The GSH content was
two fold lower compared to the control group. Lower
content of GSH could be associated with a signifi-
cantly increased demand for this metabolite during
the intensification of free radical oxidation. The treat-
ment with the hepatoprotectors allows a recovery
of 56.8% of glutathione redox level in the standard
therapy and return to the levels of control group in
the patients under the therapy aided by melaxen. This
increase correlates with changes in aMT6s and is clearly
connected with the protective effect of melatonin and
its positive action on the tissue glutathione redox
status.
The fluctuations in the catalytic and specific activ-
ities of glutathione antioxidant system enzymes (GPx,
GRx, and GST) in the control and experimental groups
before and after 10 days therapy have been analyzed.
An enhancement of GPx and GRx activities and a de-
crease in GST were observed in patients with drug-
induced hepatitis when compared to the control group.
GPx and GRx activities in the patients groups before the
therapy were 1.3- and 2.2-fold (p < 0.05) higher than the
control group. The enzymes specific activity exhibited
the same trend with the increase in 1.1- and 1.4-fold
(p < 0.05). This initial stimulation of the GPx/GRx
system could be due to its induction to counteract
the effect of uncontrolled ROS production and ox-
idative stress during the pathology development. Ox-
idative stress simultaneously enhanced the apoptotic
processes, which was reflected by the increase in the
caspases activity. Administration of the hepatoprotec-
tors through standard therapy promoted the activation
of GPx and GRx 1.2-fold (p < 0.05) and 1.1-fold, re-
spectively, when compared to the onset of the treat-
ment. This enhancement was accompanied by gains
in the GPx and GRx specific activities, which rose
18.5% (p < 0.05) and 5.3%, respectively. The GPx and
GRx activities also exceeded normal values in the pa-
tients’ blood of the second group. However its vari-
ation range is larger, when the enzymes activity be-
fore the onset and the end of therapy was compared
(Figure 3). Thus, therapy aided by melaxen resulted
in a stronger GPx and GRx activation, with an in-
crease in the catalytic activity by 2.1- and 1.8-fold and
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FIGURE 2. Variation of 6-sulfatoxymelatonin (A) and glutathione (B) content in blood serum of control group (1), in patients with drug-induced
hepatitis, at the beginning (first column) and after 10 days (second column) of traditional therapy administration (2), and traditional therapy
combined with melaxen (3): before (first column) and after (second column) therapy.
FIGURE 3. Variation of glutathione peroxidase (GPx; EC 1.11.1.9) (1) and glutathione reductase (GRx; EC 1.6.4.2) (2) catalytic activity expressed
in U/mL (A) and specific catalytic activity expressed in U/mg protein (B) in blood serum of control group (1), in patients with drug-induced
hepatitis, at the beginning (first column) and after 10 days (second column) of traditional therapy administration (2), and traditional therapy
combined with melaxen (3): before (first column) and after (second column) therapy.
specific catalytic activity by 1.4- and 1.5-fold, respec-
tively (p < 0.05). The enhancement of GPx and GRx
specific activities could indicate a possible induction of
enzymatic expression in the presence of melaxen.
The decrease in GST activity in blood serum
(Figure 4) was 1.6-fold (p < 0.05) lower, while its spe-
cific activity was 1.7-fold lower in comparison with the
control group. The decrease in GST activity may be as-
sociated with competition for GSH when its turnover
through the GPx/GRx system increases to prevent ox-
idative damage caused by ROS to the cellular and
tissue structures. Standard therapy increased GST ac-
tivity and specific activity by 1.5-fold (p < 0.05) and
1.4-fold, respectively, in comparison with the onset of
J Biochem Molecular Toxicology DOI 10.1002/jbt
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FIGURE 4. Variation of glutathione transferase (GST; EC 2.5.1.18) catalytic activity expressed in U/mL (A) and specific catalytic activity
expressed in U/mg protein (B) in blood serum of control group (1), in patients with drug-induced hepatitis, at the beginning (first column) and
after 10 days (second column) of traditional therapy administration (2), and traditional therapy combined with melaxen (3): before (first column)
and after (second column) therapy.
the therapy. This increase could be perhaps connected
with the enhancement of the GSH cellular pool as
a result of the hepatoprotectors action, which allows
GST to participate in the protective mechanism directly
neutralizing drug toxins. Similarly, the GST activity and
specific activity in the patients of the second group
has also increased by 1.8-fold (p < 0.05) and 1.7-fold
(p < 0.05), respectively, after the therapy aided by
melaxen. These data are consistent with the availability
of high cellular GSH concentration (Figure 2) promoted
by the GRx (Figure 3), which is the primary substrate
of GST acting as an acceptor of the antituberculosis
drugs. Perhaps a certain predetermined level of GSH is
needed to raise GST activity, which in turn could occur
through the enzyme induction under oxidative stress.
The activity of glutathione antioxidant system and
regeneration of GSH under oxidative stress require a
constant supply of NADPH as reduction power, which
could be supported by the work of G6PD or NADP–
IDH. However, a decrease in the G6PD activity and
specific activity of 1.5-fold (p < 0.05) and 1.4-fold, re-
spectively, was observed in blood samples of the pa-
tients when compared to the control group (Figure 5).
G6PD is a main supplier of NADPH for GSH regenera-
tion by GRx and the decrease in its activity is consistent
with GSH lowest levels and decrease in GST activity.
At the same time, the catalytic activity and the specific
activity of NADP–IDH in the blood serum of patients
groups before the therapy was 1.3- and 1.1-fold lower
than in the control group. NADP–IDH is an alternative
supplier of NADPH for GSH regeneration by GRx and
its inhibition is consistent with the observed decrease
in GSH levels and GST activity during drug-induced
hepatitis.
After the standard therapy, the activity of G6PD
and NADP–IDH increased by 25.3% and 10.6%, re-
spectively. Similarly, G6PD and NADP–IDH specific
activities raised by 1.3- and 1.1-fold, respectively
(Figure 5). This difference was evidently related to
the positive effect of the hepatoprotectors on the
hepatocytes metabolism and could be coupled with
activation of glutathione antioxidant system and GTS
(conjugation function) observed after the treatment
with carsil and/or essenthiale. The therapy aided by
melaxen showed to be even more effective and resulted
in the 1.7- and 1.2-fold increase in G6PD and NADP–
IDH activities. At the same time, G6PD and NADP–
IDH specific activities increased by 1.5-fold (p < 0.05)
and 1.2-fold. Activation of the NADPH-generating en-
zymes was higher when the standard treatment was
combined with melaxen. This activation resulted in
a significant increase in all enzymatic activities (GRx,
GPx, and GST) of the glutathione antioxidant system
(Figures 3 and 4).
Comprehensive analysis of these data indicates
that melatonin can play a role of an adaptogene capable
to promote a regulatory action on free radical home-
ostasis and apoptosis processes, positively influencing
the ROS scavenging potential of tissue through the acti-
vation of glutathione antioxidant system supported by
the NADP-supplying enzymes during oxidative stress
caused by drugs during hepatitis.
DISCUSSION
In the liver, cytochrome P450 is the defense against
cells damage performing drugs bioinactivation. Neu-
tralization of xenobiotics additionally leads to the ROS
production, inducing the oxidative stress. Oxidative
conditions can stimulate Fas ligand synthesis enhanc-
ing hepatocytes susceptibility to apoptosis [23]. The Fas
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FIGURE 5. Variation of glucose-6-phosphate dehydrogenase (G6PD; EC 1.1.1.49) (1) and NADP-dependent isocitrate dehydrogenase (NADP–
IDH; EC 1.1.1.42) (2) catalytic activity expressed in U/mL (A) and specific catalytic activity expressed in U/mg protein (B) in blood serum
of control group (1), in patients with drug-induced hepatitis, at the beginning (first column) and after 10 days (second column) of traditional
therapy administration (2), and traditional therapy combined with melaxen (3): before (first column) and after (second column) therapy.
L is exceeded in acute liver failure as a result of its ex-
pression [24] and is suggested to activate the caspases.
The enhancement of caspases activity is associated
with the oxidative stress and Fas-mediated apoptotic
processes. The increase in the caspases activity dur-
ing Fas-induced apoptosis [24] results from sequential
activation of caspase-1- and caspase-3-like proteases
[25] and can be suppressed by enzyme inhibitors [24].
The decrease in caspases activity was also associated
with hepatoprotectors, where melaxen demonstrated
the stronger effect. Melatonin positively inhibits the
apoptotic processes by enhancing the expression of an-
tiapoptotic Bcl-2 genes [26, 27]. Melaxen intake corrects
melatonin levels, attenuating free radical oxidation and
inhibiting inflammatory and apoptotic processes.
The role of melatonin in ROS neutralization can be
estimated based on aMT6s changes [19, 28], in which
reduction is associated with melatonin use as a ROS
scavenger, reacting with peroxyl radicals [29], singlet
oxygen species [30], and hydrogen peroxide with
the formation of 3-hydroxymelatonin [31]. Melatonin
metabolites including aMT6s can themselves detoxify
radicals [32, 33]. These events are named “antioxidant
cascade of melatonin” [33, 34]. The aMT6s variation in
the presence of hepatoprotectors shows an increase in
liver protection by this cascade.
The GSH variation is consistent with its direct
use in ROS scavenging [35] or indirectly in enzymatic
processes, providing tissues antioxidant defense [7].
Carsil and essenthiale promote the GSH increase, de-
creasing ROS activity. Higher GSH in the presence of
melaxen can be explained by melatonin synergistic ac-
tion on ROS scavenging and glutathione antioxidant
system activity. Enhanced glutathione antioxidant sys-
tem oxidation and reduction functions are a response
to ROS activity. GPx is induced by oxidative stress [36],
increasing the needs for GSH not sufficiently compen-
sated by the GRx. The positive effect of hepatoprotec-
tors results in an overall increase in GAS, including
conjugation (GST) function. Melatonin promotes the
NADPH-dependent GSSG reduction by GRx [37], sur-
passing the needs for GSH [38], which is consistent with
higher GRx activity in the presence of melaxen. The in-
crease in GSH and aMT6s support these observations
J Biochem Molecular Toxicology DOI 10.1002/jbt
456 POPOV ET AL. Volume 29, Number 10, 2015
and indicate that melatonin activity can be connected
with the expression of antioxidant enzymes [16]. The
decrease in GST activity may be associated with com-
petition of the GPx/GRx system for GSH. GST is a key
enzyme in drugs detoxification through conjugation
[39], removing them from the blood [10] and avoiding
the beginning of stress cascade.
G6PD activity decrease is consistent with glu-
coneogenesis hampering and glycolysis enhancement
in the injured liver [40], with the suppression of the
anaplerotic branchpoint of pentose phosphate path-
way. Suppression of the oxidative metabolism during
liver intoxication is connected with metabolic disor-
ders in hypoxic conditions [40]. Glutathione antioxi-
dant system mobilization can be limited also by the
NADP–IDH inhibition affecting the NADPH supply
[41] and GST [39]. The inhibition of NADPH supplying
enzymes might be the main causes of GSH decrease.
The distinguished effects of the hepatoprotectors with
more effective action of melaxen on the glutathione an-
tioxidant system activity are consistent with this system
induction after exposure to melatonin [42].
CONCLUSIONS
Our study demonstrated that drug-induced hep-
atitis is accompanied by a decrease in aMT6s and GSH
levels, enhancement of caspase-1 and caspase-3 activ-
ity, and disturbances of the glutathione antioxidant
system activity. The reduction of aMT6s and GSH at
pathology is explained by the dilapidation of mela-
tonin and GSH in ROS neutralization. The increase in
caspase-1 and caspase-3 activities is an indicator of un-
dergoing inflammatory and apoptotic processes medi-
ated by the Fas receptor. The decrease in GSH content
and the GST activity reflects the disturbance of glu-
tathione antioxidant system functioning under oxida-
tive stress that is not compensated by the increase in
GRx and GPx activity. Therapy with the hepatopro-
tectors aided with melaxen seems to be effective to
compensate the disorders in the function of enzyme
and nonenzyme components of the glutathione antiox-
idant system. It can be concluded that correction of
tissue oxidant–antioxidant status is an important part
of the effective therapy against drug-induced hepatitis.
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